- Home
- BCDA vs VEEE Comparison
BCDA vs VEEE Comparison
Compare BCDA & VEEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- VEEE
- Stock Information
- Founded
- BCDA N/A
- VEEE 1994
- Country
- BCDA United States
- VEEE United States
- Employees
- BCDA N/A
- VEEE N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- VEEE Marine Transportation
- Sector
- BCDA Health Care
- VEEE Industrials
- Exchange
- BCDA Nasdaq
- VEEE Nasdaq
- Market Cap
- BCDA 7.9M
- VEEE 5.7M
- IPO Year
- BCDA N/A
- VEEE 2021
- Fundamental
- Price
- BCDA $2.68
- VEEE $0.47
- Analyst Decision
- BCDA Strong Buy
- VEEE
- Analyst Count
- BCDA 1
- VEEE 0
- Target Price
- BCDA $25.00
- VEEE N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- VEEE 24.8K
- Earning Date
- BCDA 11-06-2024
- VEEE 11-11-2024
- Dividend Yield
- BCDA N/A
- VEEE N/A
- EPS Growth
- BCDA N/A
- VEEE N/A
- EPS
- BCDA N/A
- VEEE N/A
- Revenue
- BCDA $428,000.00
- VEEE $26,027,229.00
- Revenue This Year
- BCDA $6.92
- VEEE $76.99
- Revenue Next Year
- BCDA N/A
- VEEE N/A
- P/E Ratio
- BCDA N/A
- VEEE N/A
- Revenue Growth
- BCDA 0.71
- VEEE N/A
- 52 Week Low
- BCDA $1.96
- VEEE $0.33
- 52 Week High
- BCDA $23.25
- VEEE $1.77
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- VEEE 40.50
- Support Level
- BCDA $2.39
- VEEE $0.47
- Resistance Level
- BCDA $2.90
- VEEE $0.54
- Average True Range (ATR)
- BCDA 0.18
- VEEE 0.07
- MACD
- BCDA -0.00
- VEEE -0.02
- Stochastic Oscillator
- BCDA 53.70
- VEEE 4.25
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About VEEE Twin Vee PowerCats Co.
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power catamaran boats to use for fishing, diving and water skiing and commercial activities including transportation, eco-tours, fishing, and diving expeditions. Its revenue is derived from the sale of boats, motors, and trailers to its independent dealers. It has organized its business into three operating segments: The gas-powered boat segment, which manufactures and distributes gas-powered boats; The electric-powered boat segment, which is developing fully electric boats, through its controlling interest subsidiary, and its franchise segment, which is developing a standard product offering and will be selling franchises across the United States through its wholly-owned subsidiary.